Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

Abstract Background In randomised clinical trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduced cardiovascular events in patients with type 2 diabetes (T2D) at high cardiovascular risk, as compared to standard care. However, dat...

Full description

Bibliographic Details
Main Authors: David Thein, Mia Nielsen Christiansen, Ulrik Madvig Mogensen, Johan Skov Bundgaard, Rasmus Rørth, Christian Madelaire, Emil Loldrup Fosbøl, Morten Schou, Christian Torp-Pedersen, Gunnar Gislason, Lars Køber, Søren Lund Kristensen
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Heart failure
Myocardial infarction
Prognosis
Treatment
Online Access:http://link.springer.com/article/10.1186/s12933-020-01078-5

Internet

http://link.springer.com/article/10.1186/s12933-020-01078-5

Similar Items